
Division of Health Care, Quality, Financing and Purchasing Center for Operations and Pharmacy Management Pharmacy and Therapeutics Committee Meeting Minutes





8:00 AM
Hilton Garden Inn
Jefferson Blvd
Warwick, Rhode Island

P&T Members Present: David Feeney, RPh, Chairperson

Gregory Allen, MD Richard Wagner, MD Mathew Salisbury, MD L. McIntyiere Johnston, MD

Charles Gross

Rita Marcoux, Co-Chairperson

Others Present: Paula Avarista, RPh, MBA (RI Medical Assistance Program)

Karen Mariano, RPh (HP Enterprises) Kathryn Novak, RPh (First Health) Ann Bennett (HP Enterprises)

Raymond Maxim, MD (Medical Director)

P&T Members Absent Kristina Ward, Pharm D

The meeting was called to order by Chairperson Feeney at 8:15. The meeting minutes of the September 14, 2010 meeting were reviewed. All members voted in favor to accept the minutes as presented.

The public comment portion of the meeting began. Representatives from the following Pharmaceutical Manufacturing Companies gave presentations: Shire, Merck, Actelion, Gilead, Forrest and Pfizer. There were also presentations from the following: Dr. Richard Iacobucci, Dr. Jerrold Rosenberg and Phyllis Dobbins.

There were no new classes reviewed at this time. The following classes were rereviewed: Alzheimer Agents, Injectable Anticoagulants, Anticonvulsants, Antidpressants, Antiemetics, Anti-Parkinson Agents, CNS Stimulants and related agents, Antihypertensives, Lipotropics/Statins, Pulmonary Arterial Hypertension Agents, and Platelet Inhibitors. The following classes had no new entities and no changes to the current PDL preferences: Antiemetics, CNS Stimulants, Beta-blockers, Platelet Inhibitors, and Calcium Channel Blockers. The other drug classes had changes. Please refer to the chart below.

The following discussion among the committee members occurred concerning a few of the drug classes being reviewed.

Pulmonary Hypertension Drugs- The concern was that there did not seem to be continuity of treatment. Original fills with no or limited refills. DHS to look into this

Anti-Depressant- Compliance goal is not being achieved in this class. Concern that Cymbalta might be skewing the data because of the multiple uses. Same concern with Lyrica and the anti-convulsant class. DUR Program will review.

Meeting adjourned at 11:00. Next meeting April 5, 2011.

Chart

Drug Class	Drug Name	Brand/Generic	New Entity	PDL Status	Status Changed
Alzeihmer Agents	Aricept ODT	Brand	No	Non-preferred	Yes
	Rivastigmine	Generic	Yes	Preferred	
	Exelon Caps	Brand	No	Non-preferred	Yes
Anti-Convulsants	Depakote ER	Brand	No	Non-preferred	Yes
	Depakote Sprinkles	Brand	No	Non-preferred	Yes
	Divalproex ER	Generic	No	Preferred	Yes
Anit-Depressants	Paroxetine CR	Generic	No	Preferred	Yes
	Fluoxetine DR	Generic	Yes	Preferred	
Anti-Parkinson	Mirapex	Brand	No	Non-preferred	Yes
	Pramipexole	Generic	Yes	Preferred	
Anti-Hypertensives	Amlodipine-Benazepril	Generic	Yes	Preferred	
	Lotrel	Brand	No	Non-preferred	Yes
	Losartan	Generic	Yes	Preferred	
	Cozaar	Brand	No	Non-preferred	Yes
	Losartan-HCTZ	Generic	Yes	Preferred	
	Hyzaar	Brand	No	Non-preferred	Yes
	Valturna	Brand	Yes	Preferred	
	Tekamlo	Brand	Yes	Non-preferred	
	Quinapril	Generic	No	Preferred	Yes
Statins	Lescol/XL	Brand	No	Non-preferred	Yes
	Livalo	Brand	Yes	Non-preferred	
	Advicor	Brand	No	Non-preferred	Yes
Pulmonary Hypertension	Adcirca	Brand	Yes	Preferred	
Anti-Coagulants	Enoxaparin	Generic	Yes	Non-preferred	